EGFR and non-small cell lung carcinoma: The last decade has witnessed the evolving role of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKIs) as the first‐line treatment for EGFR‐mutant advanced NSCLC for their favorable efficacy and safety.10, 11, 12, 13